Endocrinology spans the entire course of life because hormones are not merely substances that can be “measured” in a blood sample, but constitute a biological language that coordinates growth, maturation, reproduction, metabolic homeostasis, stress response and adaptation to environmental changes. The same hormonal pathway assumes different meanings according to the temporal context: during fetal and neonatal development it guides tissue programming and the cardiorespiratory transition; in childhood it supports linear growth and neurocognitive maturation; during puberty it governs gonadal activation and body remodeling; in adulthood it regulates fertility and pregnancy; during the climacteric and aging it interacts with frailty, sarcopenia, cardiovascular risk and iatrogenic vulnerability. Understanding these transitions is crucial because the boundary between physiology and pathology is often defined by thresholds that change with age, biological sex and the pattern of binding to plasma proteins, and because many endocrine therapies are, in practice, replacements or modulations of signals that vary physiologically over time.
A second principle is that endocrine “normality” is strongly dependent on rhythm. Many axes show ultradian pulses, circadian oscillations and infradian cycles, with amplitude and periodicity that change predictably across the stages of life. This leads to a clinical corollary: correct interpretation of a value requires a temporal framework that includes time of day, sampling conditions, puberty or menopause, pregnancy, ongoing therapies and comorbidities. Life-course endocrine medicine therefore does not merely “change reference ranges”, but requires understanding how age remodels receptor sensitivity, hepatic and renal clearance, globulin-bound bioavailability, the response to stress and inflammation, and the likelihood that a pharmacological intervention will produce benefit or harm.
Finally, many endocrine decisions at different ages are choices aimed at preventing cumulative damage. Timely correction of congenital hypothyroidism protects neurological development; careful management of hypothyroidism or hyperthyroidism during pregnancy reduces maternal and fetal risks; appropriate use of menopausal hormone therapy requires risk stratification; glucocorticoid replacement in adrenal insufficiency must avoid both underdosing and the metabolic consequences of overdosing. The key competence becomes the ability to integrate age-related biology, evidence and patient preferences, with monitoring that takes the temporal trajectory into account, not only the isolated value at a single point in time.
A life-course approach starts from the recognition that the endocrine system is a hierarchical and redundant control system, in which each axis includes a signal source, one or more effector glands, a temporal pattern and a set of feedback loops. Across life stages, all these elements change. In the early years, anabolic patterns oriented toward growth and development predominate, with high neuroendocrine plasticity; during puberty, hypothalamic circuits are recalibrated and gonadotropin pulsatility increases; during pregnancy, the placenta introduces a transient “endocrine organ” that modifies the thyroid, adrenal gland, glucose metabolism and lipids; during the climacteric and andropause, the reduction in gonadal signals modifies body composition and bone; in older age, endocrine reserves decline and susceptibility to drug adverse effects increases. The same diagnosis can therefore carry different weight: an identical biochemical abnormality may be irrelevant in one phase, crucial in another, or require different treatment thresholds.
Physiological variability depends substantially on transport proteins. During pregnancy and with estrogen exposure, thyroxine-binding globulin (TBG) and corticosteroid-binding globulin (CBG) increase, modifying total thyroxine and cortisol levels; interpretation must prioritize free fractions or validated indices and consider analytical interferences. Nutritional and inflammatory status, more frequent in older people and in chronic disease, also alters peripheral conversion, protein binding and hypothalamic signals. One particularly sensitive axis is the thyroid axis, in which the relationship between thyroid-stimulating hormone (TSH) and free thyroxine (FT4) changes with age, pregnancy and non-thyroidal illness, requiring caution when distinguishing adaptation from treatable disease.
Endocrine pharmacology throughout life also requires attention to bioavailability and clearance. Neonates and infants have maturing hepatic metabolism and renal function, with risk of accumulation and dose instability. Young adults often have greater lean mass and higher clearance than older adults. In older patients, reduced glomerular filtration, polypharmacy and lower albumin levels increase the risk of overdose, hypoglycemia, hyponatremia, hyperkalemia or thrombotic events depending on the therapies used. In parallel, some endocrine conditions require education in self-management throughout life, such as adrenal insufficiency, in which prevention of adrenal crisis depends on the ability to increase the dose during stress and to use parenteral therapy in case of vomiting or inability to take oral treatment.
During fetal life, the endocrine system contributes to defining tissue architecture and function. The fetal thyroid gradually becomes functional and interacts with maternal supply, while fetal cortisol is crucial for lung maturation and adaptation to birth. The transition to extrauterine life involves a rapid change in temperature, oxygenation and energy supply, requiring an integrated neuroendocrine response involving catecholamines, cortisol, glucagon and insulin. In this phase, clinical vulnerability is high because small functional deviations can have disproportionate consequences for neurological development, growth and metabolic stability.
A paradigmatic example is congenital hypothyroidism, in which thyroid hormone deficiency during the first weeks and months can impair myelination, synaptic development and cognitive trajectory. For this reason, neonatal screening programs, timely initiation of therapy and close follow-up are considered pillars of public health. Effective management is not limited to starting levothyroxine, but requires titration with age-appropriate targets, assessment of adherence, evaluation of factors interfering with absorption and monitoring of growth and development, with strategies that differ from those used in adults because the nervous system is in a critical phase of maturation.
In the same phase, congenital adrenal disorders such as congenital adrenal hyperplasia require a life-course approach because early diagnosis reduces the risk of adrenal crisis and electrolyte imbalance, while replacement therapy and any surgical and psychological management have implications extending to puberty, fertility and adult quality of life. In physiological terms, the neonate is also more vulnerable to dehydration and sodium-potassium imbalance, so diseases that alter mineralocorticoids and cortisol become time-dependent emergencies requiring family education and emergency plans that continue over time.
Childhood is the phase in which the endocrine system mainly supports linear growth, bone maturation and neurocognitive development, through a balance between nutrition, the growth hormone insulin-like growth factor 1 axis (GH-IGF-1), thyroid function, vitamin D, calcium metabolism and appetite regulation. Clinical interpretation requires distinguishing normal variants such as familial short stature or constitutional delay from diseases such as growth hormone deficiency, acquired hypothyroidism or chronic diseases that depress growth through inflammation and reduced energy availability. Growth is an “integrative outcome”: deviations from the growth channel, slowing of growth velocity and discordance between chronological age and bone age guide the diagnostic pathway more than a single hormonal value.
In pediatric endocrine evaluation, understanding the relationships between adiposity, insulin and future puberty is also central. The increasing prevalence of pediatric obesity makes a structured approach necessary, including prevention, early recognition of complications and, in selected cases, pharmacological or intensive interventions. In this framework, the endocrinologist must integrate growth physiology with the pathophysiology of insulin resistance: compensatory hyperinsulinemia, alterations in adipose tissue, inflammatory signals and their impact on the liver, ovary, gonadotropin axis and cardiometabolic risk. Childhood therefore becomes a window of opportunity to reduce future disease burden through strategies that modify trajectories, not only instantaneous parameters.
Bone metabolism in pediatric age is another life-course domain. Peak bone mass is largely built during adolescence, but its foundations are laid earlier. Vitamin D deficiency, chronic diseases, glucocorticoid therapy and hypogonadism can impair mineralization and increase fracture risk. Densitometric and clinical assessment in pediatrics has specific criteria and requires caution in diagnostic terminology and in correlation with clinically significant fractures. In practical terms, this means that prevention of adult bone fragility begins with early recognition and treatment of risk factors during developmental age, with goals and thresholds that differ from those used in adulthood.
Puberty is a complex neuroendocrine transition in which the hypothalamic generator of gonadotropin-releasing hormone (GnRH) increases its pulsatile activity, with a rise in gonadotropins and gonadal steroidogenesis. This process interacts with the GH-IGF-1 axis, thyroid function, cortisol and metabolic signals such as leptin and insulin. Clinically, puberty involves rapid growth acceleration, changes in body composition, skin and psychological changes, and bone remodeling that contributes to peak bone mass. Endocrine assessment must therefore consider timing, sequence of events and family context, because the same “earliness” or “delay” has different implications for final height, psychological wellbeing and long-term risks.
In delayed puberty, the key point is to distinguish a physiological variant such as constitutional delay from hypogonadotropic or hypergonadotropic hypogonadism. This distinction is not only diagnostic: it determines the timing and modalities of intervention, the impact on self-esteem, bone density and future reproductive function. In hypergonadotropic hypogonadism, as in specific chromosomal conditions, management includes not only pubertal induction and monitoring of bone health, but also surveillance of cardiac, metabolic and auditory comorbidities, with a multidisciplinary and continuous care model over time. Puberty is also a time when eating disorders and risk behaviors may emerge or consolidate, altering the hypothalamic-pituitary-gonadal axis and the hypothalamic-pituitary-adrenal axis, with consequences for fertility and bone.
Adolescence is also a critical phase for adherence to therapy in chronic disorders. Replacement therapies such as levothyroxine, hydrocortisone or growth hormone therapy require regularity; however, adolescence brings greater autonomy, variable routines and resistance to medical follow-up. An effective life-course approach anticipates this risk: progressive education, gradual empowerment, shared emergency plans and structured transition to adult care, avoiding interruptions that may cause clinical decompensation, adrenal crises, metabolic relapses or loss of follow-up for comorbidities.
During reproductive age, endocrine physiology integrates fertility, ovarian cyclicity, thyroid homeostasis and metabolic adaptation. Pregnancy is a unique endocrine condition because it introduces a transient organ, the placenta, which produces hormones and modulates maternal axes. This leads to necessary adaptations: increased thyroid hormone production, changes in insulin sensitivity with a progressive tendency toward insulin resistance, increased binding proteins and changes in lipid metabolism. Clinical evaluation requires distinguishing physiological adaptation from disease, because excessive intervention can be as harmful as insufficient intervention, especially in a context in which maternal and fetal outcomes are closely related to hormonal stability.
The thyroid in pregnancy is a paradigm of life-course endocrinology. The requirement for thyroid hormones increases and reference values change, with implications for pre-existing hypothyroidism, subclinical hypothyroidism, thyroid autoimmunity and gestational thyrotoxicosis. The modern approach includes contextual interpretation of tests, management of iodine intake, risk assessment and therapeutic titration with maternal-fetal goals, not simply “normalization” according to non-pregnant adult reference ranges. The postpartum period also requires attention because of immune fluctuations and the possible onset of postpartum thyroiditis, with effects on nonspecific symptoms and maternal wellbeing.
Pituitary and adrenal diseases during pregnancy require a replacement strategy that takes into account changes in corticosteroid-binding globulin and the need to adjust doses during obstetric stress and delivery. In women with adrenal insufficiency, prevention of adrenal crisis requires detailed plans for intercurrent events, vomiting, labor and surgical procedures, with education of both the patient and the obstetric team. Similarly, in hypogonadism or in conditions requiring hormone replacement therapy, reproductive planning and counseling become integral parts of management, because endocrine decisions influence fertility, thrombotic risk and obstetric outcomes.
The climacteric is an endocrine transition in which ovarian function declines and estrogen and progesterone production becomes irregular until it ceases. This change results in vasomotor symptoms, sleep disturbances, mood alterations, urogenital changes and modifications in body composition. Estrogen reduction also contributes to accelerated bone remodeling and increased risk of osteoporosis, while cardiometabolic evolution depends on the interaction between hormones, visceral adiposity, blood pressure and lipid profile. A life-course approach considers this phase as a turning point, in which symptom management must not be separated from long-term risk prevention.
Menopausal hormone therapy is one of the fields most sensitive to risk stratification and timing. The decision is not simply “yes or no”, but an integrated assessment that considers age, time since menopause, thromboembolic history, cardiovascular risk, breast cancer risk, predominant symptoms, quality of life and preferences. The choice of estrogen type, route of administration, association with a progestogen in women with a uterus and treatment duration requires clear clinical logic and proactive monitoring. In the life-course model, hormone therapy is included in an overall plan that also involves lifestyle, fracture prevention, densitometric assessment when indicated and anti-osteoporotic pharmacological treatment according to risk.
One often underestimated aspect is that menopause frequently coincides with the onset or diagnosis of autoimmune thyroid disorders and with an increased prevalence of metabolic syndrome. Since symptoms can overlap, clinical evaluation must avoid simplistic attribution. In addition, polypharmacy may begin or intensify in this phase, making interactions and laboratory interferences more likely. Effective management therefore requires reasoning that distinguishes climacteric symptoms from concomitant endocrine diseases and defines realistic goals: symptom reduction, bone protection, cardiovascular prevention and preservation of sexual and urogenital function.
In adult men, the gonadal system supports sexual function, fertility, muscle mass and bone health through testosterone and its metabolites. With aging, progressive variations in total and free testosterone are observed, influenced by increased sex hormone-binding globulin (SHBG), comorbidities, adiposity and medications. The central point from a life-course perspective is to distinguish a physiological fluctuation and a reduction related to disease or obesity from true clinical hypogonadism requiring therapy. Diagnosis requires correlation of specific symptoms, appropriate repeated measurements under standardized conditions and evaluation of causes, because therapeutic intervention has safety implications for the prostate, erythrocytosis, thrombotic risk and the cardiovascular system.
Testosterone therapy, when indicated, is not an isolated intervention but a pathway: choice of formulation, objectives, clinical and laboratory monitoring and periodic reassessment of the benefit-risk balance. In parallel, many conditions that reduce testosterone are potentially reversible through weight loss, treatment of obstructive sleep apnea, optimization of diabetes and reduction of interfering medications. The life-course model therefore favors a hierarchical strategy: first identify and treat modifiable determinants, then consider replacement in appropriate cases, avoiding medicalization of age-related variations in the absence of a coherent clinical picture.
In this phase, the interaction between the gonadal axis and glucose metabolism is also frequent, because insulin resistance and visceral adiposity are associated with reduced testosterone and low-grade chronic inflammation. This produces a bidirectional circuit that may promote sarcopenia, reduced functional capacity and worsening cardiometabolic risk. Mature endocrine management therefore integrates physical activity, nutrition, cardiovascular risk assessment and, when appropriate, hormonal interventions within a framework of preventive and functional medicine.
Older age is characterized by reduced functional reserve in many systems, including endocrine axes, with increased susceptibility to acute stressors and iatrogenic changes. This does not mean that an older person “should” have pathological values, but that interpretation must consider comorbidities, inflammation, non-thyroidal illness, malnutrition, renal insufficiency and polypharmacy. A central issue is avoiding overtreatment: excessive thyroid replacement can increase the risk of atrial fibrillation and bone loss; excessive glucocorticoid replacement can induce sarcopenia and frailty; overly aggressive glycemic control can cause hypoglycemia with falls and delirium. Life-course clinical endocrinology in older patients is based on individualized targets and prevention of treatment-related harm.
Frailty and sarcopenia are examples of syndromes in which the endocrine system interacts with nutrition, inflammation and inactivity. Decline in muscle mass and strength modifies insulin sensitivity, autonomy and hospitalization risk, and may be worsened by hypogonadism, subclinical hyperthyroidism, iatrogenic hypercortisolism or vitamin D deficiency. In this framework, the most effective therapy is often multimodal: progressive physical activity, adequate protein intake, correction of specific deficiencies and medication rationalization. The role of the endocrinologist is to identify treatable components contributing to the trajectory of decline and to establish monitoring that protects function and quality of life.
A crucial practical aspect is the management of endocrine emergencies in older people, in whom symptoms may be atypical and rapidly progressive. Adrenal insufficiency may present with asthenia, hypotension and electrolyte disturbances, but also with confusion and acute worsening of pre-existing conditions; severe hypothyroidism may mimic geriatric syndromes; glycemic disorders may manifest as falls. From a life-course perspective, preventing adverse events means not only “knowing the disease”, but also preparing simple therapeutic plans, caregiver education when necessary and clear criteria for reassessment and dose adjustments during infections, surgery or therapeutic changes.
Transitions are high-risk moments for loss of follow-up and clinical decompensation. An adolescent with congenital hypothyroidism, hypopituitarism, adrenal insufficiency or congenital adrenal hyperplasia may go through a phase of discontinuity precisely when school demands, autonomy and psychosocial changes increase. If transition is not structured, the risk is interruption of essential therapies, reduced monitoring and loss of surveillance for complications. An effective model requires a gradual transition with progressive educational goals, shared documentation and clear definition of responsibilities, so that the patient enters adulthood with adequate skills for daily and emergency management.
Similarly, the transition from adulthood to geriatric care requires a rebalancing of goals. Treatments appropriate at 40 years of age may become excessive at 80 if the risk of falls, renal function and life expectancy change. Intervention thresholds for diabetes, dyslipidemia and endocrine replacements must therefore be reconsidered in light of frailty, multimorbidity and patient priorities. Life-course endocrinology here becomes pragmatic precision medicine: not “less care”, but more targeted care, with deprescribing when necessary and monitoring aimed at preventing events that compromise autonomy.
Continuity of care also includes data quality over time. Laboratory values, imaging and anthropometric measures acquire meaning when placed within a longitudinal series. A single TSH value or a single testosterone value may be poorly informative without temporal history, sampling conditions and changes in weight or medications. The most effective clinical practice therefore builds a biological narrative of the patient, in which the sequence of events and therapies explains the trajectory and guides decisions, reducing errors caused by decontextualized interpretations.